Business

Roche's Q1'26 Earnings Call: Obesity dual agonist advances as giredestrant filed in adjuvant setting

Roche's Q1 2026 earnings conference call, held April 23, 2026, centered on three converging pipeline signals: an imminent fenebrutinib NDA filing carrying an unresolved fatal AE imbalance, a giredestrant regulatory timeline anchored to the adjuvant breast cancer setting after a first-line Phase III failure, and a materially accelerated obesity franchise now entering Phase III with enicepatide while planning a mid-2026 combination study with petrelintide.

Key Strategic Signals

[Fenebrutinib / MS]: Following positive results from the FENhance 1 Phase III trial in relapsing MS — the last of three positive Phase III studies across RMS and PPMS — Roche confirmed a regulatory filing in "the coming months," executives said. Management reiterated peak sales potential above CHF 3 billion, suggesting fenebrutinib represents the first BTK inhibitor with positive Phase III data across both RMS and PPMS.

[Giredestrant / Breast Cancer]: Roche filed giredestrant in the adjuvant ER-positive, HER2-negative setting (lidERA) using a priority review voucher, with approval expected before year-end, executives said. A PDUFA date of December 18 was set for the second-line-plus evERA indication, while management reframed the commercial opportunity around adjuvant — estimated at roughly 70% of a USD 20–30 billion total SERD market — following the Phase III persevERA failure in first-line metastatic breast cancer.

[Enicepatide + Petrelintide / Obesity]: Roche initiated two Phase III obesity trials for enicepatide (formerly CT-388, a GLP-1/GIP dual agonist) in Q1 2026 and announced a Phase II combination study with petrelintide (amylin analog, partnered with Zealand) set to enroll its first patient around mid-2026, executives said. Emugrobart (RO7204239) was discontinued in SMA and FSHD following negative Phase II data, however development continues for obesity, specifically as a muscle-sparing agent in combination with weight-loss drugs.

Analyst Pressure Points

[Fenebrutinib Safety / Approvability]: Analysts pressed management on a fatal AE imbalance observed across all three fenebrutinib Phase III MS trials — including suicidality cases — and whether the FDA had signaled concern about approvability. Teresa Graham, CEO of Roche Pharmaceuticals, said discussions with the FDA had been "very productive" and that the company was "confident in the favorable risk-benefit profile," while acknowledging that suicidality in the MS population would "likely require more data and more time" to fully characterize.

The AllSci BriefSystematic R&D and deal news. Daily.

[Petrelintide Differentiation / Phase III Commitment]: An analyst from BNP Paribas questioned whether petrelintide could be considered first- or best-in-class given the competitive amylin landscape and pressed on whether Roche had internally debated committing approximately CHF 2 billion to a full Phase III program. Graham defended the asset on the basis of its placebo-like tolerability profile and its role as a combination partner for enicepatide, with CEO Thomas Schinecker adding that the combination rationale — pairing a highly tolerable amylin with a strong GLP-1/GIP — was central to the strategic thesis.

Forward-Looking Catalysts

[December 18, 2026 — Giredestrant PDUFA (evERA)]: The US FDA review of giredestrant in second-line-plus ER-positive, HER2-negative metastatic breast cancer concludes December 18, with adjuvant approval (lidERA) also expected before year-end under priority review, executives said. The unread pionERA trial — enriched to 40% ESR1-mutant patients versus 5% in persevERA — remains a 2027 first-line catalyst that management said could recover commercial opportunity in the metastatic setting.

[Mid-2026 — Enicepatide + Petrelintide Phase II FPI]: The first patient in for the enicepatide-petrelintide fixed-dose combination Phase II study is expected around mid-2026, executives said, with additional Phase II readouts for enicepatide in type 2 diabetes obesity, oral GLP-1 CT-996, and the combination all guided for before year-end 2026. Management indicated an IR event around the American Diabetes Association meeting in June would provide further detail on trial design and the combination development strategy.


This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/


Spot something wrong? Report an issue with this article